Exploring Mechanism of Key Chinese Herbal Medicine on Breast Cancer by Data Mining and Network Pharmacology Methods<sup>*</sup>

Li-na YANG; Zhu-lin WU; Zhen-jiang YANG; Shi-guang LI; Chen-sheng OUYANG

doi:10.1007/s11655-020-3422-y

Your Location：

Home >

Browse articles >

Exploring Mechanism of Key Chinese Herbal Medicine on Breast Cancer by Data Mining and Network Pharmacology Methods^*

Original Article | Updated：2021-11-29

- Exploring Mechanism of Key Chinese Herbal Medicine on Breast Cancer by Data Mining and Network Pharmacology Methods^*
- Chinese Journal of Integrative Medicine Vol. 27, Issue 12, Pages: 919-926(2021)
- Affiliations：
  
  Department of Oncology and Haematology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine,Shenzhen, Guangdong Province (518033), China
- Author bio：
  
  Prof. OUYANG Chen-sheng, E-mail:chensheng_ouyang@126.com.
- Funds：
- DOI：10.1007/s11655-020-3422-y
  CLC：
- Published：15 November 2021，
  
  Published Online：22 June 2020，
  
  Accepted：22 April 2020
Scan for full text
Li-na YANG, Zhu-lin WU, Zhen-jiang YANG, et al. Exploring Mechanism of Key Chinese Herbal Medicine on Breast Cancer by Data Mining and Network Pharmacology Methods^*. [J]. Chinese Journal of Integrative Medicine 27(12):919-926(2021)
DOI：

Li-na YANG, Zhu-lin WU, Zhen-jiang YANG, et al. Exploring Mechanism of Key Chinese Herbal Medicine on Breast Cancer by Data Mining and Network Pharmacology Methods^*. [J]. Chinese Journal of Integrative Medicine 27(12):919-926(2021) DOI： 10.1007/s11655-020-3422-y.

摘要

目的:

利用数据挖掘技术筛选治疗乳腺癌的核心中药

并利用网络药理学方法分析其潜在的作用机制.

方法:

收集治疗乳腺癌的中医临床处方

应用中医传承辅助平台(TCMISS) 筛选核心中药. 然后

利用中药系统药理学数据库与分析平台(TCMSP) 检索核心中药的活性成分和对应的靶点

并使用OMIM和MalaCards数据库获取乳腺癌的靶点基因. 随后筛选核心中药与乳腺癌的共同靶点

并构建蛋白质-蛋白质相互作用(PPI) 网络. 此外

通过Cytoscape 3.7.1构建 "核心中药-活性成分-乳腺癌-靶点" 的网络. 最后

利用David数据库进行京都基因和基因组百科全书(KEGG) 和基因本体论(GO) 分析

以揭示核心中药的作用机制.

结果:

共鉴定出7味核心中药

其有效成分包括槲皮素、木犀草素、川陈皮素、山奈酚、异鼠李素、柚皮素、β-谷甾醇等. PPI分析结果显示核心中药的关键靶点为ESR1、MYC、CCND1、EGFR、CASP3、ERBB2

KEGG通路分析富集在PI3K-Akt、p53、ErbB和HIF-1等信号通路.

结论:

基于数据挖掘和网络药理学方法

本研究发现治疗乳腺癌的核心中药可能通过影响与乳腺癌发生发展相关的靶点和通路来发挥抗乳腺癌作用.

Abstract

Objective:

To screen the key Chinese herbal medicines (KCHMs) against breast cancer by data mining

and analyze the potential mechanism of KCHMs using network pharmacology method.

Methods:

Clinical prescriptions consisted of Chinese herbal medicines for treating breast cancer were screened

and then Traditional Chinese Medicine Inheritance Support System (TCMISS) was applied to obtain the KCHMs. Subsequently

active ingredients and corresponding target genes of KCHMs were searched by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database

and target genes of breast cancer were collected using OMIM and MalaCards. After that

the overlapping target genes of KCHMs and breast cancer were screened

and the protein-protein interaction (PPI) network was built. In addition

a network of "KCHMs-active ingredients-breast cancer-targets" was constructed by Cytoscape 3.7.1. Finally

Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis were performed with Database for Annotation

Visualization and Integrated Discovery (DAVID) database to reveal the action mechanism of KCHMs.

Results:

A total of 7 KCHMs were identified

whose active ingredients include quercetin

luteolin

nobiletin

kaempferol

isorhamnetin

naringenin

and be-ta-sitosterol

etc. Based on protein-protein interaction analysis

core targets were ESR1

MYC

CCND1

EGFR

CASP3

ERBB2

etc. Several KEGG pathways (e.g

PI3K-Akt

p53

ErbB

and HIF-1 signaling pathways) were found.

Conclusion:

Based on the combination of the data mining method and network pharmacology approach

the therapeutic effect of KCHMs on breast cancer may be realized by acting on target genes and signaling pathways related to the formation and progression of breast cancer.

关键词

Keywords

breast cancerChinese medicineChinese herbal medicinepharmacology

references

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA,Jemal A. Global cancer statistics 2018: GLO-BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018;68:394-424.

Masjedi S, Zwiebel LJ, Giorgio TD. Olfactory receptor gene abundance in invasive breast carcinoma. Sci Rep 2019;9:13736.

Herrera AC, Panis C, Victorino VJ, Campos FC, Colado-Simao AN, Cecchini AL, et al. Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol, Immunother 2012;61:2193-2201.

Dieci MV, Del Mastro L, Cinquini M, Montemurro F,Biganzoli L, Cortesi L, et al. Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: development of grade (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Medical Oncology (AIOM). Cancers 2019;11:1137.

Hurvitz SA, Hu Y, O'Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treatm Rev 2013;39:219-229.

Majumder M, Debnath S, Gajbhiye RL, Saikia R, Gogoi B, Samanta SK, et al. Ricinus communis L. fruit extract inhibits migration/invasion, induces apoptosis in breast cancer cells and arrests tumor progression in vivo. Sci Rep 2019;9:14493.

Liao YH, Li CI, Lin CC, Lin JG, Chiang JH, Li TC. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017;143:2425-2435.

Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015;9:16-34.

Meng H, Peng N, Yu M, Sun X, Ma Y, Yang G, et al.Treatment of triple-negative breast cancer with Chinese herbal medicine: a prospective cohort study protocol.Medicine (Baltimore) 2017;96:e8408.

Tian H, Qin W, Wu W, Guo P, Lu Y, Liu P, et al. Effects of traditional Chinese medicine on chemotherapy-induced myelosuppression and febrile neutropenia in breast cancer patients. Evid Based Complement Alternat Med 2015;2015:736197.

Wang W, Xu L, Shen C. Effects of traditional Chinese medicine in treatment of breast cancer patients after mastectomy: a meta-analysis. Cell Biochem Biophy 2015;71:1299-1306.

Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, et al. Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2016;2016:3281968.

Liu YY, Hu D, Fan QQ, Zhang XH, Zhu YC, Ni MY, et al.Study on mechanism of Chaihu Shugan Powder for treating depression based on network pharmacology. Chin J Integr Med 2020;26:921-928.

Zeng L, Yang K. Exploring the pharmacological mechanism of Yanghe Decoction on HER2-positive breast cancer by a network pharmacology approach. J Ethnopharmacol 2017;199:68-85.

Tang SH, Shen D, Yang HJ. Analysis on composition rules of Chinese patent drugs treating pain-related diseases based on data mining method. Chin J Integr Med 2019;25:861-866.

Ru JL, Li P, Wang JN, Zhou W, Li BH, Huang C, et al.TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics 2014;6:13.

Song WJ, Ni SL, Fu YL, Wang Y. Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: a network pharmacology study. Sci Rep 2018;8:17362.

Oliveros JC. (2007-2015) Venny. An interactive tool for comparing lists with Venn's diagrams. Available at: https://bioinfogpcnbcsices/tools/venny/indexhtmlhttps://bioinfogpcnbcsices/tools/venny/indexhtml.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015;43:D447-D452.

Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization,and integrated discovery. Genome Biol 2003;4(5):P3.

Zhang Y, Li X, Xu X, Yang N. Mechanisms of Paeonia lactiflora in treatment of ulcerative colitis: a network pharmacological study. Med Sci Monit 2019;25:7574-7580.

Jia L, Huang S, Yin X, Zan Y, Guo Y, Han L. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci 2018;208:123-130.

Nguyen LT, Lee YH, Sharma AR, Park JB, Jagga S,Sharma G, et al. Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity. Kor J Physiol Pharmacol 2017;21:205-213.

Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, et al.Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression. Oncol Rep 2017;37:895-902.

Cook MT. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer 2018;10:89-100.

Sp N, Kang DY, Joung YH, Park JH, Kim WS, Lee HK, et al. Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling through PXN in ER(+) breast cancer cells. Int J Mol Sci 2017;18.

Ren J, Lu YF, Qian YH, Chen BZ, Wu T, Ji G. Recent progress regarding kaempferol for the treatment of various diseases. Exp Ther Med 2019;18:2759-2776.

Li SS, Yan T, Deng R, Jiang XS, Xiong HP, Wang Y, et al. Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of RhoA and Rac l.OncoTargets Therapy 2017;10:4809-4819.

Kim SH, Hwang KA, Choi KC. Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models. J Nutrit Biochem 2016;28:70-82.

Awad AB, Roy R, Fink CS. Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells. Oncol Rep 2003;10:497-500.

Hu S, Huang L, Meng L, Sun H, Zhang W, Xu Y. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways. Mol Med Rep 2015;12:6745-6751.

Zhao Z, Jin G, Ge Y, Guo Z. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. Inflammopharmacology 2019;27:1021-1036.

Yeo B, Turner NC, Jones A. An update on the medical management of breast cancer. BMJ 2014;348:g3608.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR,Savage H, et al. Heterogeneity and clinical sig-nificance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 2016;7:11579.

Fallah Y, Brundage J, Allegakoen P, Shajahan-Haq AN. MYC-driven pathways in breast cancer sub-types.Biomolecules 2017;7:53.

Qu J, Zhao X, Wang J, Liu X, Yan Y, Liu L, et al.MYC overexpression with its prognostic and clinico-pathological significance in breast cancer. Oncotarget 2017;8:93998-94008.

Maia LBL, Breginski FSC, Cavalcanti TCS, de Souza RLR,Roxo VMS, Ribeiro EMSF. No difference in CCND1 gene expression between breast cancer patients with and without lymph node metastasis in a Southern Brazilian sample. Clin Exp Med 2016;16:593-598.

Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metast Rev 2016;35:575-588.

Liu XF, Li JW, Chen HZ, Sun ZY, Shi GX, Zhu JM, et al.Yanghe Huayan decoction inhibits the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling. Biosci Rep 2019;39.

Himuro T, Horimoto Y, Arakawa A, Matsuoka J, Tokuda E, Tanabe M, et al. Activated caspase 3 expression in remnant disease after neoadjuvant chemotherapy may predict outcomes of breast cancer patients. Ann Surg Oncol 2016;23:2235-2241.

Rahim B, O'Regan R. AR signaling in breast cancer.Cancers 2017;9:21.

Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Ann Rev Med 2016;67:11-28.

Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.Cancer Treatment Rev 2016;45:87-96.

Liao MJ, Ye MN, Zhou RJ, Sheng JY, Chen HF. Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts. Evid Based Complement Alternat Med 2014;2014:628712.

Zhao M, Howard EW, Guo Z, Parris AB, Yang X. p53 pathway determines the cellular response to alcohol-induced DNA damage in MCF-7 breast cancer cells. PLos One 2017;12:e0175121.

Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-76.

Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophy Acta 2015;1855:276-300.

Shawky MS, Ricciardelli C, Lord M, Whitelock J, Ferro V, Britt K, et al. Proteoglycans: potential agents in mammographic density and the associated breast cancer risk. J Mamm Gland Biol Neopl 2015;20:121-131.

da Silva PL, do Amaral VC, Gabrielli V, Montt Guevara MM,Mannella P, Baracat EC, et al. Prolactin promotes breast cancer cell migration through actin cytoskeleton remodeling.Front Endocrinol 2015;6:186.

Wang Z. ErbB Receptors and cancer. Methods Mol Biol 2017;1652:3-35.

Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B 2015;16:32-43.

Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, et al. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer Res 2018;37:175.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

Mechanism Study on Chinese Medicine in Treatment of Nodular Goiter

Chinese Medicine as Supporting Therapy for Psoriasis:Past, Present, and Future

Saposhnikovia divaricata—An Ethnopharmacological, Phytochemical and Pharmacological Review

Mechanism Underlying Antitumor Effects of Sinomenine

Related Author

No data

Related Institution

Institute of Chinese Medicine, The Chinese University of Hong Kong

State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong

Department of Chemical Pathology, The Chinese University of Hong Kong

Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, STEM College, RMIT University

Li Dak Sum Yip Yio Chin R & D Centre for Chinese Medicine, The Chinese University of Hong Kong SAR

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰